Questions to Ask Before Starting Semaglutide or Tirzepatide in New Jersey
Published by New Jersey Trim Clinic · Updated 2025-04-13
Essential Questions for New Jersey GLP-1 Patients
Starting semaglutide or tirzepatide is a medical decision that deserves careful consideration. Whether you are evaluating a local clinic or a telehealth program, asking the right questions helps you choose a safe, effective provider and set realistic expectations. Here are the questions every New Jersey patient should ask.
About Your Provider
Who will be supervising my care? Treatment should be supervised by a licensed medical provider — a physician, nurse practitioner, or physician assistant. Ask about their qualifications and experience with GLP-1 medications.
Will I see the same provider at each visit, or will it change? Continuity of care matters. A provider who knows your history can make better decisions about your treatment.
How are follow-up appointments structured? Ask how often you will have check-ins and what those appointments cover. Regular monitoring is a sign of a quality program.
About the Medication
Where is the medication sourced? All medications should come from licensed U.S. pharmacies. Ask this question directly and expect a clear answer.
Is this brand-name or compounded medication? Both can be appropriate, but you should know what you are receiving. Your provider should explain the difference and why they prescribe what they do.
What is the dose-escalation schedule? GLP-1 medications are started at low doses and gradually increased. Ask your provider to walk you through the schedule they plan to follow.
About Side Effects and Safety
What are the most common side effects, and how are they managed? Any provider prescribing GLP-1 medications should be able to discuss side effects clearly and explain their approach to managing them.
What are the contraindications? Ask what health conditions would make GLP-1 medication inappropriate for you. Your provider should review your complete health history before answering this question.
What should I do if I experience concerning symptoms? Know how to reach your medical team and what symptoms require immediate attention.
About Cost and Commitment
What is the total monthly cost, and what is included? Get a clear, written answer about everything the monthly fee covers.
Are there any additional fees? Ask about enrollment fees, consultation charges, cancellation penalties, or any other costs.
Is there a contract or commitment period? Understand whether you can stop treatment at any time without penalties.
About Expectations
What results can I realistically expect? Be cautious of any provider who guarantees specific weight loss numbers. Individual results vary based on many factors.
How long should I plan to be on medication? Discuss the expected timeline for treatment and what happens when you reach your goals.
What lifestyle changes should I make alongside medication? GLP-1 medications work best when combined with sustainable lifestyle modifications. Your provider should discuss nutrition, activity, and other factors.
Using These Questions
These questions apply whether you are considering a telehealth program, a local clinic, a chain weight loss center, or any other provider. A quality program will welcome these questions and provide clear, honest answers.
New Jersey Trim Clinic is happy to answer all of these questions during your free consultation. We believe informed patients make better decisions. Programs start at $149 per month, all-inclusive. Individual results vary.
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.
Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.
- FDA — Wegovy (semaglutide) prescribing information
Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.
Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.
- Tirzepatide Once Weekly for the Treatment of Obesity
Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.
Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. New England Journal of Medicine. 2021.
Research published in the New England Journal of Medicine reported greater weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo in the studied adults without diabetes.
- Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. New England Journal of Medicine. 2022.
Research published in the New England Journal of Medicine reported dose-dependent weight reduction with tirzepatide versus placebo over 72 weeks in the studied population.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.